UniQure N.V. reported first‑quarter 2026 results on May 5, 2026, with revenue of $3.6 million, a net loss of $53.5 million, and a basic loss per share of $0.85. Revenue grew 125 % year‑over‑year, driven by a $2.0 million increase in license revenue, while research and development expenses fell to $29.2 million, a $6.9 million reduction from the prior year. Selling, general and administrative costs rose to $20.1 million, up from $10.9 million in Q1 2025, reflecting hiring for AMT‑130 commercial planning.
The company’s revenue fell short of consensus estimates of $4.5 million, missing by roughly 20 %. The miss reflects the small base of the business and the fact that, although license revenue grew, overall product sales did not offset the lower revenue base. Analysts had expected a higher contribution from commercial sales, which did not materialize in the quarter.
Earnings per share beat expectations, with a loss of $0.85 versus consensus estimates ranging from $-0.88 to $-0.75. The beat of $0.03 to $0.10 per share was largely attributable to disciplined cost management, including the $6.9 million reduction in R&D spending and the controlled increase in SG&A, which together helped offset the revenue shortfall.
Cash, cash equivalents and current investment securities totaled $586.6 million as of March 31, 2026, giving the company a runway that extends into the second half of 2029. The strong liquidity position provides a buffer for continued investment in the AMT‑130 pipeline and other programs while maintaining operational flexibility.
Regulatory activity remains a key focus. A Type B meeting with the U.S. Food and Drug Administration is scheduled for Q2 2026 to discuss a new clinical trial design for AMT‑130. In the United Kingdom, the company successfully completed a pre‑submission meeting with the Medicines and Healthcare products Regulatory Agency and is preparing a marketing‑authorization application for the third quarter of 2026.
CEO Matthew Kapusta said, “During the first quarter of 2026, we remained focused on advancing AMT‑130 to patients globally as rapidly as possible while executing across our broader pipeline.” He added, “We believe our data continue to support the potential for AMT‑130 to fundamentally change the treatment landscape for Huntington’s disease, and we look forward to continued engagement with the FDA.”
Analysts have responded to the earnings by upgrading the stock and raising price targets, citing the company’s strong cash position and progress in the UK regulatory pathway. However, the firm’s revenue miss and the FDA’s requirement for a more rigorous Phase III trial remain significant headwinds that investors are monitoring closely.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.